logo

IPO

Share

inventiva jan05 The lockup period of Inventiva SA (IVA) ends on January 6. Daix, France-based Inventiva is a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, mucopolysaccharidoses, or MPS, and other diseases.

poseidatherapeutics jan05 The lockup period of Poseida Therapeutics (PSTX) ends tomorrow, i.e., January 6. San Diego, California-based Poseida Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat a range of cancers.

nkarta jan05 The lockup period of Nkarta Inc. (NKTX) expires tomorrow, i.e. on Jan 6. South San Francisco, California-based Nkarta Inc. is a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer.

MEDIROM Healthcare Technologies Inc. (MRM) said that it has priced its initial public offering of 800,000 American Depositary Shares at a price of US$15.00 per ADS. Each ADS represents one common share of MEDIROM. The ADSs are expected to begin trading on the Nasdaq Capital Market on December 29,...

Qualtrics International Inc. has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $100 million in an initial public offering of common shares. Qualtrics has filed the initial public offerings, just about two years after it was acquired by German...

inhibikasetherapeutics dec23 Inhibikase Therapeutics is scheduled to make its debut on the Nasdaq Global Select Market today (December 23), under the ticker symbol "IKT." Atlanta, Georgia-based Inhibikase Therapeutics is a clinical stage pharmaceutical company developing therapeutics kinase inhibitors for Parkinson's disease and related disorders.

fusionpharmaceuticals dec22 The lockup period of Fusion Pharmaceuticals Inc. (FUSN) ends on December 23.. Canada-based Fusion Pharmaceuticals is a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines based on its proprietary platform called Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology.

akouos dec22 The lockup period of Akouos Inc. (AKUS) expires tomorrow, i.e. on Dec. 23. Boston, Massachusetts-based Akouos is a precision genetic medicine company developing adeno-associated virus, or AAV delivered gene therapies for various hearing loss conditions.

polypid 1222 The lockup period of PolyPid Ltd. (PYPD) ends tomorrow, i.e., December 23. PolyPid is a clinical-stage biopharmaceutical company developing prolonged-release therapeutics for surgical site infections using its proprietary PLEX technology.

Follow RTT